Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Section 3 of 6

Product information and disease description

284 evidence topics · 115 sources

Product description

Phase of product development

Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Formulation, fill volume, and storage

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

Special populations
Pregnancy and lactation

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Ersodetug

No evidence found.

Effects of Ersodetug on other drugs

No evidence found.

Dosing and administration
Dosage
Administration
Access and distribution
Specialty pharmacy or distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Ersodetug on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators
Direct comparisons of ersodetug with other therapies

No evidence found.

Place of product in therapy

Disease description

Definition and etiology
Tumor types named by the manufacturer: insulinoma and non-islet cell tumors
Epidemiology
Incidence of Tumor hyperinsulinism
Prevalence of Tumor hyperinsulinism
Natural history, survival, and mortality
Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort

“Overall survival was analysed with Kaplan–Meier and Cox regression analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the multivariate analyses, older age and distant metastases were associated with decreased survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pathophysiology
Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability

“Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Insulinoma: supervised prolonged fasting test
NICTH: biochemical pattern and IGF-2 to IGF-1 ratio
Clinical presentation - signs and symptoms
Long-term morbidity
NICTH: long-term morbidity

No evidence found.

Burden of Tumor hyperinsulinism
Humanistic burden and health-related quality of life
Health-related quality of life in non-islet cell tumor hypoglycemia

No evidence found.

Economic burden and healthcare resource utilization
Cost-of-illness or claims-based cost studies of insulinoma or NICTH

No evidence found.

Economic impact of Tumor hyperinsulinism on families

Not applicable.

Economic impact of diagnostic testing
Cost of diagnostic testing for tumor hyperinsulinism

No evidence found.

Approaches to treatment

Current treatment options and standard of care
Surgical resection
Resection of localized insulinoma: NANETS surgical guideline

“Resection of a localized insulinoma results in a 98% biochemical cure rate with a 6% chance of recurrence at 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the case of insulinoma, the morbidity associated with an extensive pancreatic mobilization and 10% risk of non-palpable or non-visible tumors outweigh the low-risk of malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Therefore, surgical exploration or blind resection of the tail of the pancreas are not recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with a localized, biochemically confirmed, functional PNET should be resected because clinical syndromes associated with each are significant, even when small in size. Furthermore, with the exception of insulinoma, the majority have significant malignant potential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Criteria for selection of patients for enucleation have not been defined, but expert opinion suggests that enucleation should be reserved for smaller tumors, those more likely to display benign behavior (such as insulinomas or NF-PNETs <2 cm), and that are located >2–3 mm from the main pancreatic duct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Curative resection and debulking for insulinoma: clinical review

“For single solitary insulinomas, curative surgical excision remains the treatment of choice. However, it should be performed only when the diagnosis is certain and by a surgeon who is skilled in pancreatic surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Complications following pancreas resection include postoperative pancreatic fistula, postpancreatectomy hemorrhage, and delayed gastric emptying together with exocrine and endocrine pancreatic insufficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In aggressive malignant cases, debulking of the panNEN, including locoregional lymph nodes can be considered on a case-by-case basis, particularly in an attempt to control the endogenous hyperinsulinemic hypoglycemia (54, 103, 118).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“If more than 90% of tumor load can be resected, palliative surgery can also be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment (54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Surgery among recovered and deceased patients with IGF-2-mediated NICTH
Endoscopic ultrasound-guided ablation
Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison

“Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Dietary measures and parenteral glucose or glucagon
Diazoxide
Indication, dosing, warnings, and adverse reactions: diazoxide prescribing information

“PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: • Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.” (opens the source at this quote in a new tab)

“PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.” (opens the source at this quote in a new tab)

“When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered.” (opens the source at this quote in a new tab)

“Adults and children: The recommended starting dosage is 3 mg/kg/day, administered orally, divided into 3 equal doses every 8 hours or 2 equal doses every 12 hours. The dosage may be titrated to a maximum of 8 mg/kg/day. Patients with refractory hypoglycemia may require higher dosages.” (opens the source at this quote in a new tab)

“If administration of PROGLYCEM is not effective after 2 or 3 weeks, discontinue PROGLYCEM.” (opens the source at this quote in a new tab)

“The antidiuretic property of diazoxide may lead to significant fluid retention. In patients with compromised cardiac reserve, fluid retention may precipitate congestive heart failure.” (opens the source at this quote in a new tab)

“Ketoacidosis and nonketotic hyperosmolar coma have been reported in patients treated with PROGLYCEM, usually during intercurrent illness.” (opens the source at this quote in a new tab)

“Hirsutism of the lanugo type, mainly on the forehead, back and limbs, occurs most commonly in children and women and may be cosmetically unacceptable.” (opens the source at this quote in a new tab)

“Thrombocytopenia with or without purpura may require discontinuation of PROGLYCEM.” (opens the source at this quote in a new tab)

Somatostatin analogs
Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review
mTOR inhibitors
Peptide receptor radionuclide therapy
Systemic antitumor therapy
Cytotoxic chemotherapy and sunitinib in malignant insulinoma: effect on hypoglycemia
Liver-directed therapy
Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases

“Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After the first HAE, median HFS was 14.5 months, and median OS was 16 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“IV fluids containing dextrose given preprocedurally in 85% (n = 17) of patients were stopped either immediately postprocedure, on resumption of oral intake, or before discharge, in all patients after the first HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Glucocorticoids and recombinant growth hormone
Glucocorticoids and recombinant growth hormone in NICTH: clinical review

“In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Glucocorticoids (including dexamethasone, hydrocortisone, prednisolone, and prednisone, typically in doses equivalent to prednisone 30–60 mg/d) are the most extensively described medical therapy for NICTH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Combination therapy was successful (including freedom from iv glucose or dextrose) in multiple cases where monotherapy with either failed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although there are no randomized controlled trials to guide therapy, ample case reports and series are available in the literature over the past quarter century.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Limitations of current therapies
Summary: surgery and ablation for benign and localized insulinoma
  • Surgical resection is the guideline treatment for localized insulinoma. The NANETS surgical guideline gives a 98% biochemical cure rate and a 6% chance of recurrence at 10 years after resection of a localized insulinoma.
  • Operative morbidity is the main limitation. In 198 patients (106 enucleations and 92 pancreatic resections), the rate of clinically significant pancreatic fistula was 18%, enucleations had a higher reoperation rate than pancreatic resections (8.5% vs 1%), and new exocrine (1.5%) and endocrine (4%) insufficiency followed pancreatic resections only. In 80 patients operated for sporadic insulinoma over three decades, mortality was 6% (n = 5), morbidity 72%, and pancreatic fistula 44%, although surgery was curative in all patients. In 74 patients, an open approach (28 patients) was associated with more grade III/IV complications (32.1% vs 19.6%) and more 30-day readmissions (42.9% vs 17.4%) than a minimally invasive approach (46 patients).
  • Recurrence after resection was 21% at 10 and 20 years in patients with MEN I, and 5% at 10 years and 7% at 20 years in patients without MEN I, in one cohort.
  • EUS-guided radiofrequency ablation is an option in ENETS guidance for localized insulinomas of 2 cm or less in patients unfit for surgery, with confinement to expert centers until long-term survival and recurrence data are available. In a propensity-matched comparison of 89 patients per group, adverse events occurred in 18.0% after ablation and 61.8% after surgery, clinical efficacy was 95.5% and 100%, median follow-up was 23 and 37 months, and 15 lesions (16.9%) recurred after ablation. A randomized trial comparing ablation with surgery (NCT05735912) is registered.
Summary: medical therapy for hypoglycemia in insulinoma
  • Dietary measures (fractioned meals with slowly absorbed carbohydrates, bedtime meals) are the basis of hypoglycemia control; nocturnal tube feeding or IV glucose through a central catheter may be needed in severe recurrent hypoglycemia. The glucagon (Gvoke) label lists insulinoma as a contraindication because glucagon may stimulate insulin release from the tumor, and states that the product is not approved for continuous infusion.
  • Diazoxide is the first-line medical therapy for advanced insulinoma in ENETS guidance and controls hypoglycemia in 50 to 60% of cases according to the NANETS surgical guideline. Dose-limiting adverse effects (fluid retention and edema, palpitations, nausea, anorexia, hirsutism) occur in up to 80% of patients in one review. The label directs discontinuation if diazoxide is not effective after 2 or 3 weeks and warns of fluid retention that may precipitate congestive heart failure, ketoacidosis, nonketotic hyperosmolar coma, and thrombocytopenia. In 20 patients with insulinoma, diazoxide was effective in 9 and ineffective in 9, all 9 responders had benign insulinoma, and 5 patients had unacceptable thrombocytopenia. In 6 patients with inoperable insulinoma, 5 developed edema and 2 congestive heart failure. In a UK survey of 40 patients, side effects occurred in 47%, 59% were symptom free, and 38% had occasional symptoms.
  • Somatostatin analogs can paradoxically aggravate hypoglycemia by suppressing glucagon, so a monitored trial of short-acting octreotide is advised before a long-acting formulation. Octreotide was effective in 10 of 17 patients in one series and 14 of 21 in another. The octreotide LAR and lanreotide labels warn of hypoglycemia or hyperglycemia, and their quoted indications are acromegaly, carcinoid and VIPoma symptoms, and progression-free survival in GEP-NETs. Pasireotide is used off-label; in 17 published cases, 6 (35%) showed no improvement, with no improvement in 55% of aggressive and 16% of indolent insulinomas.
  • Glucocorticoids for refractory hypoglycemia rest on incidental descriptions in ENETS guidance (level of evidence 5, grade D), and chronic use carries weight gain, neuropsychiatric disturbances, hypertension, and opportunistic infections.
Summary: malignant and metastatic insulinoma
  • In 121 patients with malignant insulinoma, resection was performed in 64%, and 5-year overall survival was 84% with surgery and 14% without. A clinical review states that most aggressive malignant metastatic insulinomas “cannot be cured by surgery or ablation procedures alone” and require medical and antitumor treatment.
  • Hypoglycemia control in one malignant insulinoma cohort was 93% with PRRT, 68% with capecitabine-temozolomide, 62% with everolimus, 37.5% with somatostatin analogs, 33.3% with chemotherapy, and 28.6% with streptozocin.
  • Everolimus: ENETS guidance describes limited tolerance. In 12 patients with metastatic insulinoma and refractory hypoglycemia, median time to first recurrence of symptomatic hypoglycemia was 6.5 months, and 3 patients discontinued for cardiac or pulmonary adverse events, which led to two deaths. The manufacturer of ersodetug states that mTOR inhibitors are used off-label.
  • PRRT requires demonstrated somatostatin receptor expression and carries a 2% rate of serious bone marrow disease. In 15 patients treated with lutetium Lu 177 dotatate, hypoglycemia resolved in 14 and recurred in 7 of 14 after a median of 17.7 months; G3/4 myelosuppression occurred in 4 of 15 and hypoglycemia flare requiring hospitalization over 48 hours in 7 of 15. In 26 patients, 5 (19%) had transient hypoglycemia after injection, and hormonal crisis occurred in 3 of 34 patients (9%) with functioning pancreatic tumors in another series.
  • Cytotoxic chemotherapy causes considerable toxicities, and evidence for an independent effect of chemotherapy regimens on hypoglycemia is lacking according to one review.
  • Liver-directed therapy carries a high morbidity risk with high hepatic metastatic load in ENETS guidance. After bland hepatic artery embolization in 20 patients, hypoglycemia recurred in 60% at a median of 2 months; after chemoembolization and radioembolization in 7 patients, mean time to recurrence of intractable hypoglycemia was 21 months.
  • The manufacturer states that tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or non-islet cell tumors, and that such therapies are deferred because of hypoglycemia.
Summary: non-islet cell tumor hypoglycemia
  • Complete surgical resection is curative for hypoglycemia, but in many cases total resection is delayed or not feasible. In a systematic review of published cases of IGF-2-mediated hypoglycemia, surgery was used in 110 cases (47.2%), and the overall recovery rate was 77% (172 of 223 cases with outcomes).
  • When prompt resection is not feasible, IV glucose or dextrose often does not suffice. Continuous glucagon infusion and parenteral nutrition are limited by the need for continuous IV infusion, and long-term parenteral nutrition is “not a desirable long-term strategy” because of venous access complications, bloodstream infections, liver toxicity, electrolyte imbalances, and cost. In a series of 4 patients with NICTH and liver metastases, glucose did not rise after glucagon in 2.
  • Diazoxide and octreotide have no role in NICTH in one clinical review, which found diazoxide unsuccessful in every case reviewed. In the systematic review, octreotide was used in 9 recovered patients (5.2%) and 9 who died (17.6%) (p = .01). The manufacturer states that diazoxide and somatostatin analogs are not effective for hypoglycemia from IGF-2 tumors.
  • Glucocorticoids, used in 91 cases (39.1%) in the systematic review, are effective only above a patient-specific dose threshold. Minimum effective doses in one review of solitary fibrous tumors were 25 mg/day of prednisolone, 32 mg/day of methylprednisolone, and 2 mg/day of dexamethasone, and recurrence below these thresholds limits long-term use. Recombinant growth hormone at 3 to 12 mg daily has been successful in many cases, cost may limit long-term use, and growth hormone may increase serum big IGF-II. No randomized controlled trials guide therapy.
Place in treatment, anticipated use, and care setting
Summary: place in therapy
  • Ersodetug is investigational and has no approved indication. The FDA orphan drug designation names the treatment of hypoglycemia due to tumor-associated hyperinsulinism, the FDA breakthrough therapy designation names hypoglycemia caused by tumor HI, and the European Union orphan designation (12 January 2024) names insulinoma.
  • The studied use is add-on therapy. The phase 3 upLIFT trial enrolls adults 18 years and older with an islet cell or non-islet cell tumor and biochemical evidence of tumor hyperinsulinism who have not achieved adequate control with usual standard-of-care therapies and require IV glucose infusion and/or parenteral nutrition for 7 days or more. Participants receive ersodetug 9 mg/kg weekly for 8 weeks “as an add-on to standard of care”, then may continue in long-term extension at a dosing frequency of every 2 to 4 weeks. Of the 16 enrolled participants, 12 have malignant islet cell tumors (insulinomas) and 4 have non-islet cell tumors.
  • In the expanded access publication, all 8 individuals had received and were refractory to at least 3 standard-of-care therapies (diazoxide, somatostatin analogs, everolimus, and/or corticosteroids), and 6 of 8 were hospitalized at entry. Ersodetug was given intravenously over 30 minutes, and the manufacturer states that hospitalized patients were discharged and received maintenance doses as outpatients. Expanded access continues through a registered program (NCT07262970), with drug supplied at no cost under compassionate use programs.
  • The manufacturer describes medical therapy as needed from diagnosis to surgery, when surgery is contraindicated or refused, and chronically in patients who cannot be cured by surgery, and names peri-operative management of solitary or benign tumors and solitary or benign tumors where surgery may not be ideal as potential additional settings. It expects to focus its launch on National Cancer Institutes and academic medical centers, where it believes 60% of patients are managed (about 1,000 prescribers and 300 centers), and expects payers to require prior authorization aligned to the label with a step through diazoxide for patients with insulinoma, with reimbursement through a J-code (buy and bill).
  • A 2024 clinical review of insulinoma reports successful use of RZ358 in one patient with malignant insulinoma and severe refractory hypoglycemia.
Studied use: add-on to standard of care in adults requiring continuous intravenous glucose
Heterogeneity of treatment effect
Ersodetug: response by tumor type (insulinoma or NICTH) in upLIFT

No evidence found.

Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Current multimodal therapy in metastatic insulinoma: hypoglycemia control and survival